Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
9.77
-0.05 (-0.51%)
At close: Dec 5, 2025, 4:00 PM EST
9.96
+0.19 (1.94%)
After-hours: Dec 5, 2025, 7:14 PM EST
Design Therapeutics Stock Forecast
Stock Price Forecast
According to 2 professional analysts, the 12-month price target for Design Therapeutics stock ranges from a low of $13 to a high of $14. The average analyst price target of $13.5 forecasts a 38.18% increase in the stock price over the next year.
Price Target: $13.50 (+38.18%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Design Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Hold | 3 | 3 | 3 | 3 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 1 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Hold → Buy Upgrades $7 → $14 | Hold → Buy | Upgrades | $7 → $14 | +43.30% | Dec 3, 2025 |
| RBC Capital | RBC Capital | Hold → Buy Upgrades $6 → $13 | Hold → Buy | Upgrades | $6 → $13 | +33.06% | Nov 20, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $5 → $6 | Hold | Maintains | $5 → $6 | -38.59% | Nov 6, 2025 |
| RBC Capital | RBC Capital | Hold Reiterates $4 | Hold | Reiterates | $4 | -59.06% | Aug 6, 2024 |
| Piper Sandler | Piper Sandler | Hold → Buy Upgrades $6 → $12 | Hold → Buy | Upgrades | $6 → $12 | +22.82% | May 7, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.30
from -0.88
EPS Next Year
-1.30
from -1.30
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.31 | -1.03 | ||||
| Avg | -1.30 | -1.30 | ||||
| Low | -1.28 | -1.52 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.